(NASDAQ: IGMS) Igm Biosciences's forecast annual revenue growth rate of -9.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Igm Biosciences's revenue in 2025 is $2,681,000.On average, 2 Wall Street analysts forecast IGMS's revenue for 2025 to be $774,582,754, with the lowest IGMS revenue forecast at $105,201,383, and the highest IGMS revenue forecast at $1,443,964,126. On average, 1 Wall Street analysts forecast IGMS's revenue for 2026 to be $186,356,736, with the lowest IGMS revenue forecast at $186,356,736, and the highest IGMS revenue forecast at $186,356,736.
In 2027, IGMS is forecast to generate $233,246,495 in revenue, with the lowest revenue forecast at $233,246,495 and the highest revenue forecast at $233,246,495.